alexa Clinical Studies of Molecular Targeted Therapy for Mult
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Clinical Studies of Molecular Targeted Therapy for Multiple Myeloma

Tsutomu Kobayashi, Junya Kuroda*, Miki Kiyota, Ryuko Nakayama and Masafumi Taniwaki

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan

*Corresponding Author:
Junya Kuroda MD, PhD
Division of Hematology and Oncology
Department of Medicine, Kyoto Prefectural University of Medicine
465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan
Tel: 081 75 251 5740
Fax: 081 75 251 5743
E-mail: [email protected]

Received Date: October 28, 2011; Accepted Date: December 03, 2011; Published Date: December 05, 2011

Citation: Kobayashi T, Kuroda J, Kiyota M, Nakayama R, Taniwaki M (2011) Clinical Studies of Molecular Targeted Therapy for Multiple Myeloma. Translational Medic S2:002. doi:10.4172/2161-1025.S2-002

Copyright: © 2011 Kobayashi T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells which still remains incurable despite conventional and high-dose chemotherapies. With the introduction of new agents, such as bortezomib, thalidomide, and lenalidomide, there has been significant improvement in treatment outcomes for MM during the last decade. Furthermore, several new novel agents those offer further possibilities for MM patients have become available clinical trials. Nevertheless, it is unclear the appropriate usage of these agents to obtain optimal survivals, for example, whether sequencing of drugs or multi-agent combinations offer the superiority. In this review we will describe the various classes of novel agents being used for MM treatment, including proteasome inhibitors, immunomodulatory drugs, histone deacetylase inhibitors, monoclonal antibodies, and other novel agents, with particularly focus on their mechanisms and clinical efficacy.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version